Elsevier

Clinical Therapeutics

Volume 31, Issue 6, June 2009, Pages 1177-1191
Clinical Therapeutics

Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period

https://doi.org/10.1016/j.clinthera.2009.05.022Get rights and content

Abstract

Objective: This trial investigated the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 μg in the treatment of breakthrough pain in opioid-tolerant patients with cancer.

Methods: This Phase III, double-blind, randomized, placebo-controlled, crossover trial was conducted at pain centers, anesthesiology departments, palliative care units, and oncology clinics in Austria, Denmark, France, Germany, and Poland. Eligible patients were adults with cancer receiving a stable dose of long-term opioid treatment for the control of background pain. Patients were treated at home with their effective dose of INFS (50, 100, or 200 μg) or inactive spray (placebo) in a randomized sequence for 3 weeks, followed by a 10-month, open-label tolerability phase during which they received their effective dose of INFS. Throughout the study, patients were allowed to use their usual rescue medication, which was recorded in patient diaries. The primary efficacy end point was the pain intensity difference at 10 minutes after study drug administration (PID10), as assessed using an 11-point numeric rating scale (0 = no pain to 10 = worst pain imaginable). An effect size of 0.5 for PID was considered clinically relevant. The rate of response, defined as PID10 >2, was also assessed. Adverse events (AEs) were recorded in patient diaries during the efficacy period and reported in monthly clinic visits and follow-up weekly telephone contacts during the extension period.

Results: In all, 120 patients were enrolled and achieved an effective dose; 113 were randomized and 111 were included in the intent-to-treat analysis set (56 men, 55 women; mean [SD] age, 60.6 [9.45] years; mean weight, 70.3 kg [men] and 65.3 kg [women]; white race, 107 [96.4%]; INFS 50 μg, 18; INFS 100 μg, 48; INFS 200 μg, 45; placebo, 110). PID10 with INFS was 2-fold that with placebo (adjusted means, 2.36 vs 1.10; adjusted difference, 1.26 [greater than the clinically relevant difference of 0.5]; P < 0.001). Additional analysis revealed that the mean response rate with all 3 doses of INFS was 51.1% versus 20.9% with placebo. The prevalence of AEs was 22/111 (19.8%) during the efficacy period, during which the most frequently reported AEs were nausea (5 [4.5%]) and vertigo (2 [1.8%]). No serious AEs were considered related to the study drugs. In all, 108 patients entered the extension period, with a mean duration of exposure to INFS of 134.9 days. Progression of underlying malignant disease was the most common AE reported during this period (55 [50.9%]); this event was not considered treatment related.

Conclusions: In these opioid-tolerant patients with cancer, INFS at doses of 50, 100, and 200 μg was associated with an onset of activity at 10 minutes and effective treatment of breakthrough pain compared with placebo. All doses were generally well tolerated and clinically efficacious.

References (46)

  • LL Christrup et al.

    Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study

    Clin Ther.

    (2008)
  • K Moksnes et al.

    Early pharmacokinetics of nasal fentanyl: Is there a significant arterio-venous difference?

    Eur J Clin Pharmacol.

    (2008)
  • E Kremer et al.

    Measurement of pain: Patient preference does not confound pain measurement

    Pain

    (1981)
  • JT Farrar et al.

    Defining the clinically important difference in pain outcome measures

    Pain

    (2000)
  • JT Farrar et al.

    Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients

    J Natl Cancer Inst.

    (1998)
  • H Brown et al.
  • D Foster et al.

    Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery

    Ann Pharmacother

    (2008)
  • RB Patt et al.

    Breakthrough pain in cancer patients: Characteristics, prevalence, and treatment

    Oncology (Williston Park)

    (1998)
    RB Patt et al.

    Breakthrough pain in cancer patients: Characteristics, prevalence, and treatment

    Oncology (Williston Park)

    (1998)
  • G Zeppetella et al.

    Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice [published correction appears in J Pain Symptom Manage. 2001;21:265]

    J Pain Symptom Manage

    (2000)
  • P Klepstad et al.

    Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network

    Palliat Med

    (2005)
  • SL Collins et al.

    Peak plasma concentrations after oral morphine: A systematic review

    J Pain Symptom Manage

    (1998)
  • PH Coluzzi et al.

    Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)

    Pain

    (2001)
  • O Dale et al.

    Nasal administration of opioids for pain management in adults

    Acta Anaesthesiol Scand

    (2002)
  • Cited by (134)

    • The use of rapid onset fentanyl in children and young people for breakthrough cancer pain

      2017, Scandinavian Journal of Pain
      Citation Excerpt :

      Manufacturer guidance should be followed for other preparations as there is minimal control over the actual dose taken. In opioid tolerant adults with cancer pain intranasal fentanyl has been shown to be effective and generally well tolerated [22]. In paediatrics its use has mainly been confined to emergency medicine where it is administered predominantly to opioid naïve children with acute pain or fractures [6,23,24].

    • Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial

      2016, Journal of Pain and Symptom Management
      Citation Excerpt :

      It has a bioavailability of 80% and a time to maximal effect (Tmax) of 15–20 minutes, making it a potential appealing option for breathlessness.17,18 FPNS has been found in clinical trials to provide greater and more rapid breakthrough pain relief than placebo19,20 and oral morphine21,22 and was generally well tolerated.23 The efficacy of FPNS has never been examined for dyspnea.

    View all citing articles on Scopus
    View full text